NO20003807L - <alfa>-ketoamidinhibitorer av 20S proteasome - Google Patents

<alfa>-ketoamidinhibitorer av 20S proteasome

Info

Publication number
NO20003807L
NO20003807L NO20003807A NO20003807A NO20003807L NO 20003807 L NO20003807 L NO 20003807L NO 20003807 A NO20003807 A NO 20003807A NO 20003807 A NO20003807 A NO 20003807A NO 20003807 L NO20003807 L NO 20003807L
Authority
NO
Norway
Prior art keywords
proteasome
alpha
ketoamide inhibitors
ketoamide
inhibitors
Prior art date
Application number
NO20003807A
Other languages
English (en)
Other versions
NO327049B1 (no
NO20003807D0 (no
Inventor
Lisa Wang
Robert T Lum
Steven R Schow
Alison Joly
Suresh Kerwar
Michael M Wick
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of NO20003807D0 publication Critical patent/NO20003807D0/no
Publication of NO20003807L publication Critical patent/NO20003807L/no
Publication of NO327049B1 publication Critical patent/NO327049B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043Leu-amino acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
NO20003807A 1998-01-26 2000-07-25 alfa-ketoamid forbindelser samt farmasoytisk sammensetning innholdende slike NO327049B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/013,365 US6075150A (en) 1998-01-26 1998-01-26 α-ketoamide inhibitors of 20S proteasome
PCT/US1999/001097 WO1999037666A1 (en) 1998-01-26 1999-01-19 α-KETOAMIDE INHIBITORS OF 20S PROTEASOME

Publications (3)

Publication Number Publication Date
NO20003807D0 NO20003807D0 (no) 2000-07-25
NO20003807L true NO20003807L (no) 2000-09-25
NO327049B1 NO327049B1 (no) 2009-04-14

Family

ID=21759598

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003807A NO327049B1 (no) 1998-01-26 2000-07-25 alfa-ketoamid forbindelser samt farmasoytisk sammensetning innholdende slike

Country Status (20)

Country Link
US (2) US6075150A (no)
EP (1) EP1058689A1 (no)
JP (1) JP3863370B2 (no)
KR (1) KR100417888B1 (no)
CN (1) CN1289340A (no)
AR (1) AR012781A1 (no)
AU (1) AU747835B2 (no)
BR (1) BR9907256A (no)
CA (1) CA2319150C (no)
GE (1) GEP20032869B (no)
HU (1) HUP0100901A3 (no)
IL (2) IL137475A0 (no)
NO (1) NO327049B1 (no)
NZ (1) NZ505892A (no)
PL (1) PL202504B1 (no)
RU (1) RU2192429C2 (no)
TW (1) TW593339B (no)
UA (1) UA71559C2 (no)
WO (1) WO1999037666A1 (no)
ZA (1) ZA99161B (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US6921751B1 (en) * 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
WO2002070467A1 (en) * 2001-02-26 2002-09-12 4Sc Ag Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
JP2005515254A (ja) 2002-01-17 2005-05-26 スミスクライン ビーチャム コーポレーション カテプシンk阻害剤として有用なシクロアルキルケトアミド誘導体
NZ575692A (en) 2002-04-11 2009-10-30 Vertex Pharma Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3-NS4 Protease
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
ES2510840T3 (es) * 2004-05-10 2014-10-21 Onyx Therapeutics, Inc. Compuestos para la inhibición enzimática del proteosoma
EP1637529A1 (en) 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US20070027067A1 (en) * 2005-05-13 2007-02-01 Felicia Etzkorn Transition-state Inhibitors of Pin1, alpha-Ketoamide-containing peptidomimetics, and synthesis thereof
SG163567A1 (en) * 2005-07-05 2010-08-30 Biotempt Bv Treatment of tumors
WO2007014925A1 (en) 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis c virus
RU2436787C2 (ru) 2005-07-29 2011-12-20 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
US8716322B2 (en) 2005-11-09 2014-05-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US8594771B2 (en) * 2005-12-28 2013-11-26 General Electric Company Devices and methods for self-administered ECG examinations
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
NZ597545A (en) 2006-06-19 2013-07-26 Proteolix Inc Peptide epoxyketones for proteasome inhibition
NZ578956A (en) * 2007-02-12 2012-02-24 Biotempt Bv Treatment of trauma hemorrhage with short oligopeptides
US8859021B2 (en) * 2007-05-14 2014-10-14 Sytheon Skin appearance through gene manipulation
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
JP5734656B2 (ja) 2007-10-04 2015-06-17 オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. ペプチドエポキシケトンプロテアーゼ阻害剤結晶及びアミノ酸ケトエポキシドの調製
DK2730581T3 (en) 2008-06-17 2016-08-15 Millennium Pharm Inc Boronate Ester Compounds and Pharmaceutical Compositions thereof.
EA024364B1 (ru) 2008-10-21 2016-09-30 Оникс Терапьютикс, Инк. Способ лечения множественной миеломы
EP3021120A1 (en) 2009-02-20 2016-05-18 Michael P. Lisanti Diagnosis, prognosis, therapeutics and methods for treating neoplastic deiseases comprising determining the level of caveolin-1 in a stromal cell sample
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
AU2010341530B2 (en) 2009-12-22 2016-03-10 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
EP2555621A4 (en) 2010-04-07 2014-07-02 Onyx Therapeutics Inc CRYSTALLINE EPOXYCETONE PEPTIDE IMMUNOPROTEASOME INHIBITOR
CN103930785B (zh) 2011-08-11 2016-05-18 詹森药业有限公司 用于癌症治疗的预测物
WO2013063481A1 (en) 2011-10-28 2013-05-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to nae inhibitors
WO2013071163A2 (en) 2011-11-11 2013-05-16 Millennium Pharamaceuticals, Inc. Biomarkers of response to proteasome inhibitors
US20160008382A1 (en) 2012-01-24 2016-01-14 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
WO2014055543A2 (en) 2012-10-01 2014-04-10 Millennium Pharmaceuticals, Inc. Biomarkers and methods to predict response to inhibitors and uses thereof
KR20150065885A (ko) * 2012-10-11 2015-06-15 에프. 호프만-라 로슈 아게 케토아마이드 이뮤노프로테아좀 억제제
WO2014172627A1 (en) 2013-04-19 2014-10-23 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
AU2015264272A1 (en) 2014-05-20 2016-11-24 Millennium Pharmaceuticals, Inc. Boron-containing proteasome inhibitors for use after primary cancer therapy
JP6859559B2 (ja) * 2017-03-16 2021-04-14 二村 芳弘 抗アレルギー作用を呈するフェニルペプチド誘導体
JP7219473B2 (ja) * 2017-08-28 2023-02-08 静岡県公立大学法人 コリバクチンおよびコリバクチン産生菌の検出方法および検出プローブ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206078B (it) * 1987-06-03 1989-04-14 Polifarma Spa Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico
JPH04211648A (ja) * 1990-07-27 1992-08-03 Nippon Kayaku Co Ltd ケト酸アミド誘導体
US5430022A (en) * 1990-05-14 1995-07-04 Fujisawa Pharmaceutical Co., Ltd. Peptide compound and its preparation
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5834487A (en) * 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones

Also Published As

Publication number Publication date
HUP0100901A3 (en) 2001-11-28
IL137475A (en) 2006-10-05
NZ505892A (en) 2002-10-25
AR012781A1 (es) 2000-11-08
NO327049B1 (no) 2009-04-14
TW593339B (en) 2004-06-21
KR100417888B1 (ko) 2004-02-11
GEP20032869B (en) 2003-01-27
WO1999037666A1 (en) 1999-07-29
BR9907256A (pt) 2001-10-09
UA71559C2 (en) 2004-12-15
AU2326799A (en) 1999-08-09
EP1058689A1 (en) 2000-12-13
US6781000B1 (en) 2004-08-24
US6075150A (en) 2000-06-13
IL137475A0 (en) 2001-07-24
AU747835B2 (en) 2002-05-23
JP3863370B2 (ja) 2006-12-27
RU2192429C2 (ru) 2002-11-10
CN1289340A (zh) 2001-03-28
CA2319150A1 (en) 1999-07-29
NO20003807D0 (no) 2000-07-25
HUP0100901A2 (hu) 2001-08-28
ZA99161B (en) 1999-07-28
PL343269A1 (en) 2001-08-13
JP2002501080A (ja) 2002-01-15
PL202504B1 (pl) 2009-06-30
KR20010034381A (ko) 2001-04-25
CA2319150C (en) 2004-08-31

Similar Documents

Publication Publication Date Title
NO20003807L (no) &lt;alfa&gt;-ketoamidinhibitorer av 20S proteasome
DK1022334T3 (da) Hidtil ukendte amylaser
IS5574A (is) Útskiptir Xa-þáttar oxóasaheterósýklýl-tálmar
ATE430158T1 (de) Hepatitis c tripeptide inhibitoren
ATE222256T1 (de) Polymorphe form von clopidogrel-hydrogenosulfat
DE69936997D1 (de) Paletteneinrichtung
EP1110149A4 (en) Collaborative object architecture
DK1105422T3 (da) Hepatitis C-inhibitorpeptider
NO20030885L (no) Inhibitorer av &lt;alfa&gt;4 styrt celleadhesjon
EP1052692A4 (en) CONTAINER
DE69910714D1 (de) Pflanzenaktivierungsmittel
DE69922097D1 (de) Kessel
DE60008353D1 (de) Hemihydrat von 16.alpha.-bromoepiandrosterone
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
DE60142754D1 (de) Electrophoretische Kasette zur Detektion von Biopolymeren
DE59803815D1 (de) Klärschlammvererdung
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
FI982378A0 (fi) Järjestely kohteen tutkimiseen
NO20012276L (no) Identifisering av SENV-genotyper
NO20010280L (no) &lt;Alfa&gt;-aminosyrefenylesterderivater
FR2783036B1 (fr) Agencement de lampes indicatrices
ITUD980038A0 (it) Indicatore di livello
KR980003137U (ko) 퇴수를 재공급 사용토록 한 개량부동전
ID22787A (id) Nitro-benzamida berguna sebagai zat anti - arritimia
FI980930L (fi) Alus

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees